Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDH305 in Advanced Malignancies With IDH1R132 Mutations
NCT02381886Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Mar 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 1, open-label, single-arm trial of idh305 in advanced cancer, sponsored by Novartis. Primary endpoint: Incident rate of dose limiting toxicities at 21 days. Started Mar 2015; status: active, not recruiting.
02
Drugs
idh305
03
Conditions
advanced cancer
Beyond the preview
Go deeper on NCT02381886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02381886.